Teva Chief Seeks Growth Beyond $40.5 Billion Allergan Deal

  • Israeli company may target specialty assets next, CEO says
  • Enlarged business has 338 treatments awaiting FDA approval

Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generics unit, which closed Tuesday, doesn’t signal that the Israeli drugmaker will let up its quest for innovative branded medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.